gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLCgastro-j-1162Research ArticleКЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИCLINICAL GUIDELINESКлинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению эрозивноязвенных поражений желудка и двенадцатиперстной кишкиRussian gastroenterological association clinical guidelines on diagnostics and treatment of NSAIDs-associated erosive and ulcerative lesions of the stomach and duodenumИвашкинВ. Т.IvashkinV. T.ШептулинА. А.SheptulinA. A.МаевИ. В.MayevI. V.БаранскаяЕ. К.BaranskayaYe. K.ТрухмановА. С.TrukhmanovA. S.ЛапинаТ. Л.LapinaT. L.ГБОУ ВПО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Минздрава РоссииРоссияState educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian FederationRussian FederationГБОУ ВПО «Московский государственный медико-стоматологический университет им. А. И. Евдокимова» Минздрава РоссииРоссияState educational government-financed institution of higher professional education «Yevdokimov Moscow State University of Medicine and Dentistry», Ministry of Healthcare of the Russian FederationRussian Federation2014240420242468994Copyright © Ивашкин В.Т., Шептулин А.А., Маев И.В., Баранская Е.К., Трухманов А.С., Лапина Т.Л., 20142014Ивашкин В.Т., Шептулин А.А., Маев И.В., Баранская Е.К., Трухманов А.С., Лапина Т.Л.Ivashkin V.T., Sheptulin A.A., Mayev I.V., Baranskaya Y.K., Trukhmanov A.S., Lapina T.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/1162
.
.
ReferencesКаратеев А.Е., Успенский Ю.П., Пахомова И.Г., Насонов Е.Л. Комбинированное лечение язв желудка, индуцированных нестероидными противовоспалительными препаратами. Результаты 4-недельного открытого контролируемого исследования по оценке эффективности комбинации ингибитора протонного насоса и висмута трикалия дицитрата. Тер арх 2009; 6:62-7.Каратеев А.Е., Успенский Ю.П., Пахомова И.Г., Насонов Е.Л. Комбинированное лечение язв желудка, индуцированных нестероидными противовоспалительными препаратами. Результаты 4-недельного открытого контролируемого исследования по оценке эффективности комбинации ингибитора протонного насоса и висмута трикалия дицитрата. Тер арх 2009; 6:62-7.Рекомендации Российской Гастроэнтерологической Ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых (Ивашкин В.Т., Маев И.В., Лапина Т.Л., Шептулин А.А. и др.). Рос журн гастроэнтерол гепатол колопроктол 2012; 22(1):87-9.Рекомендации Российской Гастроэнтерологической Ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых (Ивашкин В.Т., Маев И.В., Лапина Т.Л., Шептулин А.А. и др.). Рос журн гастроэнтерол гепатол колопроктол 2012; 22(1):87-9.Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis VIGOR Study Group. N Engl J Med 2000; 343:1520-8.Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis VIGOR Study Group. N Engl J Med 2000; 343:1520-8.Chan F.K., Graham D.Y. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications – review and recommendations based on risk assessment. Aliment Pharmacol Ther 2004; 19:105161.Chan F.K., Graham D.Y. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications – review and recommendations based on risk assessment. Aliment Pharmacol Ther 2004; 19:105161.Chan F.K., To K.F., Wu J.C.Y., et al. A randomized double-blind trial to evaluate the gastroduodenal safety of oral meloxicam 7,5 mg once daily compared with oral piroxicam 20 mg once daily over a period of f our weeks in patients with osteoarthritis of the knee [Abstract]. Gut 2004; 53(suppl. 6):119.Chan F.K., To K.F., Wu J.C.Y., et al. A randomized double-blind trial to evaluate the gastroduodenal safety of oral meloxicam 7,5 mg once daily compared with oral piroxicam 20 mg once daily over a period of f our weeks in patients with osteoarthritis of the knee [Abstract]. Gut 2004; 53(suppl. 6):119.Dajani E.Z., Islam K. Cardiovascular and gastrointestinal toxicity of selective cyclooxygenase-2 inhibitors in man. J Physiol Pharmacol 2008; 59 (suppl. 2):117-33.Dajani E.Z., Islam K. Cardiovascular and gastrointestinal toxicity of selective cyclooxygenase-2 inhibitors in man. J Physiol Pharmacol 2008; 59 (suppl. 2):117-33.Deepak L.B., Scheiman J., Abraham N.S., et al. ACCF/ACG/AHA 2008 Expert Consensus Document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation 2008; 118:1894-909.Deepak L.B., Scheiman J., Abraham N.S., et al. ACCF/ACG/AHA 2008 Expert Consensus Document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation 2008; 118:1894-909.Hawkey C.I., Wight N.J. NSAIDs and gastrointestinal complications. LSC Life Science Communications. London, 2001:1-56.Hawkey C.I., Wight N.J. NSAIDs and gastrointestinal complications. LSC Life Science Communications. London, 2001:1-56.Lanas A. A review of the gastrointestinal safety data – a gastroenterologist’s perspective. Rheumatology 2010; 49(suppl. 2):3-10.Lanas A. A review of the gastrointestinal safety data – a gastroenterologist’s perspective. Rheumatology 2010; 49(suppl. 2):3-10.Laponte J.-R., Ibanes L., Vidal X., et al. Upper gastrointestinal bleeding associated with the use of NSAIDs. Newer versus older agents. Drug Suf 2004; 27:411-20.Laponte J.-R., Ibanes L., Vidal X., et al. Upper gastrointestinal bleeding associated with the use of NSAIDs. Newer versus older agents. Drug Suf 2004; 27:411-20.Malfertheiner P., Megraud F., O’Morain C., et al. Management of Helicobacter pylori infection – the Maastricht IV Florence Consensus report. Gut 2012; 61:646-64.Malfertheiner P., Megraud F., O’Morain C., et al. Management of Helicobacter pylori infection – the Maastricht IV Florence Consensus report. Gut 2012; 61:646-64.McCarthy D.M. Non-steroidal anti-inflammatory drugs: reducing the risks to the gastrointestinal drug. Clin Perspect Gastroenterol 1999; 2:219-26.McCarthy D.M. Non-steroidal anti-inflammatory drugs: reducing the risks to the gastrointestinal drug. Clin Perspect Gastroenterol 1999; 2:219-26.Richy F., Bruvere O., Ethgen O., et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Pheum Dis 2004; 63:759-66.Richy F., Bruvere O., Ethgen O., et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Pheum Dis 2004; 63:759-66.Roth S.H. Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety. Clin Interv Aging 2011; 6:125-31.Roth S.H. Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety. Clin Interv Aging 2011; 6:125-31.Silverstein F.E. Improving the gastrointestinal safety of NSAIDs. The development of misoprostol – from hypothesis to clinical practice. Dig Dis Sci 1998; 43:447-58.Silverstein F.E. Improving the gastrointestinal safety of NSAIDs. The development of misoprostol – from hypothesis to clinical practice. Dig Dis Sci 1998; 43:447-58.Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with cеlеcoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled study. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247-55.Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with cеlеcoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled study. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247-55.Spechler S.J. Peptic ulcer and its complications. Sleisenger & Fordtran’s Gastrointestinal and Liver Disease. Philadelphia-London-Toronto-Montreal-SydneyTokyo 2002; 1:747-81.Spechler S.J. Peptic ulcer and its complications. Sleisenger & Fordtran’s Gastrointestinal and Liver Disease. Philadelphia-London-Toronto-Montreal-SydneyTokyo 2002; 1:747-81.Straube S., Tramer M.R., Moore M.A. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAIDS use. BMC Gastroenterology 2009; 9:41 doi:10.1186/1471-23OX-9-41Straube S., Tramer M.R., Moore M.A. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAIDS use. BMC Gastroenterology 2009; 9:41 doi:10.1186/1471-23OX-9-41Targownik L.E., Thomson P.A. Gastroprotective strategies among NSAID users. Guidelines for appropriate use in chronic illness. Can Pharm Physician 2006; 52:110005.Targownik L.E., Thomson P.A. Gastroprotective strategies among NSAID users. Guidelines for appropriate use in chronic illness. Can Pharm Physician 2006; 52:110005.Vane J.R., Botting R.M. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104(3A):2-8.Vane J.R., Botting R.M. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104(3A):2-8.Wallace J.L. Non-steroidal anti-inflammatory drugs and gastropathy: the second hundred years. Gastroenterology 1997; 112:1000-16.Wallace J.L. Non-steroidal anti-inflammatory drugs and gastropathy: the second hundred years. Gastroenterology 1997; 112:1000-16.Wilder-Smith C.H., Robert J., Schindler D. Upper gastrointestinal tract mucosal injury by AZD3582. A COXinhibiting nitric oxide donor and naproxen: a randomized, double-blind, crossover study in healthy subjects [Abstract]. Gut 2004; 53(suppl. 6):36.Wilder-Smith C.H., Robert J., Schindler D. Upper gastrointestinal tract mucosal injury by AZD3582. A COXinhibiting nitric oxide donor and naproxen: a randomized, double-blind, crossover study in healthy subjects [Abstract]. Gut 2004; 53(suppl. 6):36.
The authors declare that there are no conflicts of interest present.